Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

May 4th 2023

The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Neoadjuvant Atezolizumab Followed by Adjuvant Atezolizumab May Benefit Select Patients With Early-stage NSCLC

May 3rd 2023

Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.

Updates in Gender-Based Treatment for Patients with Advanced NSCLC

May 2nd 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.

Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC

May 2nd 2023

Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.

First-line Cemiplimab Plus Chemo Wins Approval in Canada for Advanced NSCLC

May 2nd 2023

Health Canada has approved the combination of cemiplimab and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer without EGFR, ALK, or ROS1 aberrations who are not candidates for definitive chemoradiation.

Dr Skoulidis on Determinants of KRAS G12C Inhibitor Efficacy in NSCLC

May 1st 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses molecular determinants of KRAS G12C inhibitor efficacy in advanced non–small cell lung cancer.

Dr Lisberg on Emerging Post-Osimertinib Treatment Options in EGFR-mutant NSCLC

May 1st 2023

Aaron Lisberg, MD, discusses ongoing and future efforts to expand effective treatment options for patients with osimertinib-resistant, EGFR-mutant non–small cell lung cancer.

Dr Murciano-Goroff on the Investigation of KRAS G12C Inhibitor LY3537982 in Solid Tumors

April 28th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the investigation of the novel KRAS G12C inhibitor LY3537982 in patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies

April 28th 2023

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer

April 28th 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

CTLA-4 Targeted Regimens in Advanced NSCLC

April 26th 2023

Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.

Dr Stewart on the Multiomic Landscape of Squamous Cell Lung Cancer

April 26th 2023

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

VT3989 Shows Activity, Tolerability in Mesothelioma and Other NF2-Mutated Solid Tumors

April 26th 2023

VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.

ASTRO/ESTRO Release Clinical Guideline for Local Therapy in Oligometastatic NSCLC

April 26th 2023

The American Society for Radiation Oncology and European Society for Radiotherapy & Oncology have released the first clinical guideline on the use of definitive local therapy, including radiation and surgery, for the treatment of patients with oligometastatic non–small cell lung cancer.

Furmonertinib Plus Icotinib Elicits Antitumor Activity in EGFR+ NSCLC With CNS Metastases

April 26th 2023

First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.

Subgrouping Patients with Advanced NSCLC for Tailored Treatment

April 25th 2023

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Overview of PD-L1 Testing in Advanced NSCLC

April 25th 2023

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

AZD3759 Elicits Responses in Untreated EGFR-Mutant NSCLC With CNS Metastases

April 25th 2023

AZD3759 elicited clinical responses and had an acceptable toxicity profile when administered at a dose of 200 mg twice daily in patients with untreated EGFR-mutant non–small cell lung cancer and central nervous system metastases, according to data from the phase 2 TRUMP trial.

Durvalumab Plus Chemo Is Tolerable in Real-World Representative ES-SCLC Population

April 25th 2023

First-line durvalumab plus up to 6 cycles of platinum and etoposide is safe and tolerable with signals of clinical efficacy consistent with those previously seen in patients with treatment-naïve extensive-stage small cell lung cancer.

Dr Herbst on the Implications of the AEGEAN Trial in NSCLC

April 24th 2023

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.